FDA ODE IV reorganization gives H. pylori reviews to new Division of Special Pathogens & Immunologic Drugs.
Executive Summary
FDA H. PYLORI THERAPY REVIEWS ASSIGNED TO DIVISION OF SPECIAL PATHOGENS and Immunologic Drug Products under a reorganization of the Office of Drug Evaluation IV. The new review division (HFD-590) was created to assume some of the workload of the Divisions of Anti-Infective Drug Products and Anti-Viral Drug Products May 12. Drug categories to be reviewed by the immunologic drugs division include drugs for non-viral opportunistic infections in AIDS patients, anti-mycobacterial drugs, solid organ transplant drugs, systemic anti-fungals including liposomal amphotericin products, vaginal anti-fungals, quinolone antibiotics not intended for ear/nose/throat indications, anti-parasitics, treatments for Helicobacter pylori, vaginal products for HIV and immunomodulating drugs, including some indications of thalidomide.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth